Harrow (HROW) Non-Current Assets (2010 - 2026)
Harrow (HROW) posted Non-Current Assets of $187.5 million for Q2 2026, down 2.93% on a QoQ basis from $193.2 million in Q1 2026, and down 1.39% year-over-year from $190.1 million in Q2 2025.
Analysis
Harrow (HROW) Non-Current Assets (2010 - 2026) Analysis & Trends
Harrow has reported Non-Current Assets for 16 years, with the latest figure at $187.5 million in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 1.39% year-over-year to $187.5 million in Q2 2026; TTM through Jun 2026 was $753.9 million, a 4.4% decrease from a year earlier, with the FY2025 full-year figure at $187.7 million, down 5.81% from the prior year.
- Non-Current Assets was $187.5 million for Q2 2026 at Harrow, down from $193.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $204.5 million in Q3 2024, with the low at $107000.0 in Q4 2022.
- Average Non-Current Assets over 5 years is $114.3 million, with a median of $171.4 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets tumbled 74.03% in 2022, then surged 161285.05% in 2023.
- Over 5 years, Non-Current Assets stood at $107000.0 in 2022, then soared by 161285.05% to $172.7 million in 2023, then climbed by 15.43% to $199.3 million in 2024, then retreated by 5.81% to $187.7 million in 2025, then decreased by 0.12% to $187.5 million in 2026.
- The last three Non-Current Assets figures came in at $187.5 million (Q2 2026), $193.2 million (Q1 2026), and $187.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.04 Bn | 624.28 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 440.25 Bn | 433.68 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 365.65 Bn | 358.51 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 159.77 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 113.37 Bn |
| 7 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - | 294.93 Mn |
| 8 | Incyte | 25.29 Bn | 20.75 Bn | 1.57 Bn | 1.85 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 3.74 Bn |
| 10 | Harrow | 1.41 Bn | 1.33 Bn | 50.36 Mn | 187.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 187.51 Mn |
| Mar 31, 2026 | 193.16 Mn |
| Dec 31, 2025 | 187.73 Mn |
| Sep 30, 2025 | 185.47 Mn |
| Jun 30, 2025 | 190.14 Mn |
| Mar 31, 2025 | 194.63 Mn |
| Dec 31, 2024 | 199.32 Mn |
| Sep 30, 2024 | 204.48 Mn |
| Jun 30, 2024 | 167.24 Mn |
| Mar 31, 2024 | 170.08 Mn |
| Dec 31, 2023 | 172.68 Mn |
| Sep 30, 2023 | 780,000.00 |
| Jun 30, 2023 | 808,000.00 |
| Mar 31, 2023 | 902,000.00 |
| Dec 31, 2022 | 107,000.00 |
| Sep 30, 2022 | 994,000.00 |
| Jun 30, 2022 | 773,000.00 |
| Mar 31, 2022 | 411,000.00 |
| Dec 31, 2021 | 412,000.00 |
| Sep 30, 2021 | 36,000.00 |